Autologous stem cell therapy - Biotech Holdings

Drug Profile

Autologous stem cell therapy - Biotech Holdings

Alternative Names: Microbiome optimized autologous stem cells - Biotech Holdings; ProCell activated stem cells - Biotech Holdings

Latest Information Update: 20 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Biotech Holdings
  • Class Antineoplastics; Cardiovascular therapies; Stem cell therapies
  • Mechanism of Action Cell replacements; Hepatocyte growth factor modulators; Immunosuppressants; Regulatory T-lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Peripheral vascular disorders
  • Preclinical Autoimmune disorders

Most Recent Events

  • 16 Oct 2017 Biotech Holdings files for patent protection with the USPTO for Reverse abscopal effect with ProCell activated stem cell therapy in USA
  • 16 Oct 2017 Preclinical trials in Autoimmune disorders in USA (Parenteral) before October 2017
  • 10 Oct 2017 Biotech Holdings files for patent protection for a mechanism of action of ProCell stem cell therapy for Peripheral vascular disorders
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top